ArticleThe journal of headache and pain2016
Network meta-analysis of migraine disorder treatment by NSAIDs and triptans.
Article in The journal of headache and pain, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 5 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Comparative efficacy of AAC and ibuprofen versus lasmiditan, ubrogepant, and rimegepant for the acute treatment of episodic migraine in adults: a systematic review and network meta-analysis.Frontiers in neurology · 2026Pooled it
- Comparative effects of drug interventions for the acute management of migraine episodes in adults: systematic review and network meta-analysis.BMJ (Clinical research ed.) · 2024Pooled it
- Lasmiditan for Acute Treatment of Migraine in Adults: A Systematic Review and Meta-analysis of Randomized Controlled Trials.CNS drugs · 2020Pooled it
- Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials.CNS drugs · 2020Pooled it
- Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition.Cephalalgia : an international journal of headache · 2019Guideline
- A review on gut microbiota and migraine severity: a complex relationship.Inflammopharmacology · 2026Review
- The use of triptans and other acute treatments for the management of migraine in routine clinical practice in England: a retrospective cohort study using the Clinical Practice Research Datalink (CPRD).BMC primary care · 2025Article
- Acute headache treatment in idiopathic intracranial hypertension: treating to the phenotype?The journal of headache and pain · 2025Article
- Trends in Triptan Usage in Korea: A Population-Based Cohort Study.Journal of Korean medical science · 2024Article
- Migraine and Its Treatment from the Medicinal Chemistry Perspective.ACS pharmacology & translational science · 2024Review
- Simultaneous Comparisons of 25 Acute Migraine Medications Based on 10 Million Users' Self-Reported Records From a Smartphone Application.Neurology · 2023Article
- Migraine and Current Pharmacologic Management.Cureus · 2022Article
- Article
- Article
- The effectiveness and value of novel acute treatments for migraine.Journal of managed care & specialty pharmacy · 2020Article
- A Comprehensive Review of Over-the-counter Treatment for Chronic Migraine Headaches.Current pain and headache reports · 2020Review
- Mechanisms of migraine as a chronic evolutive condition.The journal of headache and pain · 2019Review
- Efficacy of triptans for the treatment of acute migraines: a quantitative comparison based on the dose-effect and time-course characteristics.European journal of clinical pharmacology · 2019Review
- Liposomal Curcumin Enhances the Effect of Naproxen in a Rat Model of Migraine.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
- Migraine and cluster headache - the common link.The journal of headache and pain · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMigraine is a neurological disorder resulting in large socioeconomic burden. This network meta-analysis (NMA) is designed to compare the relative efficacy and tolerability of non-steroidal anti-inflammatory agents (NSAIDs) and triptans.
methodsWe conducted systematic searches in database PubMed and Embase. Treatment effectiveness was compared by synthesizing direct and indirect evidences using NMA. The surface under curve ranking area (SUCRA) was created to rank those interventions.
resultsEletriptan and rizatriptan are superior to sumatriptan, zolmitriptan, almotriptan, ibuprofen and aspirin with respect to pain-relief. When analyzing 2 h-nausea-absence, rizatriptan has a better efficacy than sumatriptan, while other treatments indicate no distinctive difference compared with placebo. Furthermore, sumatriptan demonstrates a higher incidence of all-adverse-event compared with diclofenac-potassium, ibuprofen and almotriptan.
conclusionThis study suggests that eletriptan may be the most suitable therapy for migraine from a comprehensive point of view. In the meantime ibuprofen may also be a good choice for its excellent tolerability. Multi-component medication also attracts attention and may be a promising avenue for the next generation of migraine treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.